Topic Hub
11 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 11 of 11 clinical reviews.
Zepbound (tirzepatide) is FDA-approved for obesity, not diabetes, that role belongs to Mounjaro. Here is what the clinical trial data show, how physicians approach off-label prescribing, and what patients should know before starting.
Read clinical reviewZepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn about its off-label use for type 2 diabetes, the clinical evidence from SURPASS trials, and the monitoring your clinician should follow.
Read clinical reviewZepbound (tirzepatide) is FDA-approved for obesity, not diabetes. This evidence summary covers the clinical trial data, off-label prescribing rationale, and how it compares to Mounjaro for blood-sugar control.
Read clinical reviewZepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn the evidence behind off-label use for type 2 diabetes, how it compares to Mounjaro, risks, and what clinicians consider before prescribing.
Read clinical reviewA clinical evidence review of tirzepatide (Zepbound) for heart failure, covering trial data from SUMMIT and STEP-HFpEF, FDA-approved indications, and what the research shows about cardiac outcomes.
Read clinical reviewCan Zepbound (tirzepatide) treat heart failure? Review the off-label evidence from SURMOUNT-HFpEF trials, FDA-approved indications, cardiovascular risks, and what clinicians consider before prescribing.
Read clinical reviewTirzepatide (Zepbound) is not FDA-approved for heart failure, but clinical trial data in HFpEF shows meaningful symptom improvement. Learn the evidence, monitoring requirements, and what clinicians need to track.
Read clinical reviewTirzepatide (Zepbound) is not FDA-approved for PCOS, but emerging trial data suggest meaningful improvements in ovulation, insulin resistance, and androgen levels. Here's what clinicians and patients need to know about off-label use.
Read clinical reviewTirzepatide (Zepbound) is not FDA-approved for PCOS, but emerging evidence supports off-label use. Learn what monitoring is required, what the trials show, and how clinicians approach prescribing.
Read clinical reviewClinical evidence for using Zepbound (tirzepatide) off-label to treat obstructive sleep apnea, including SURMOUNT-OSA trial data, AHI reductions, and prescribing considerations.
Read clinical reviewTirzepatide (Zepbound) is being used off-label for obstructive sleep apnea. Review the SURMOUNT-OSA trial data, monitoring protocols, and what clinicians need to know about prescribing Zepbound for OSA.
Read clinical review